ShareSpot

With the end of the national and public health emergency declarations for COVID-19 on May 11, 2023, it's a good time to reflect on the journey we started nearly three years ago. The outbreak of a new and unknown disease brought many challenges, but for some, it was not their first pandemic experienc...

Impact of vaccination on incidence and severity of MPOX

Two recent studies from the CDC give insight into the impact of MPOX (formerly called monkeypox) vaccination in preventing infection, and on the severity of symptoms in those who became infected after vaccination.

The first examined the effect of...

Cicatelli Associates, Inc.'s TAP-in project created the national Imagine: Ending HIV. It’s Possible. (Imagine) campaign to inspire the HIV workforce to end the epidemic by reducing the number of new HIV infections by 90 percent by 2030. The Imagine campaign aims to improve staff’s leadership capacit...

The DoxyPEP Study evaluated the efficacy of doxycycline taken as post-exposure prophylaxis (PEP) on incidence of bacterial sexually transmitted infections (STIs), chlamydia (CT), gonorrhea (GC), and syphilis, in men who have sex with men (MSM) and transgender women (TGW).¹ It was based on the earlie...

HIV care providers look to Integrating HIV Innovative Practices (IHIP) for evidence-based, evidence-informed, and emerging HIV care strategies they can adopt and integrate into their practice settings. With a library of over 75 user-friendly resources designed to address needs and gaps in services a...

The FDA recently granted approval to lenacapavir (LEN), a novel long-acting HIV antiretroviral (ARV) that is classified as a capsid inhibitor. Lenacapavir is marketed in the United States as Sunlenca.

Lenacapavir blocks HIV-1’s assembly of its protein capsid and interferes with other steps in HIV rep...

A key study from 2022, the ANCHOR Study, proved that treatment of high-grade precursors to anal cancer can prevent the development of anal cancer in people with HIV (PWH).  

Rates of anal cancer are substantially higher in PWH (both women and men) than in people without HIV. In a process analogous to...

Honoring our colleagues who dedicate additional time and resources to research beyond the scope of the AETC Program, we present the updated list of HIV-related peer-reviewed studies published in 2022 by AETC-affiliated researchers and faculty.

If you're aware of other HIV-related peer-reviewed publi...

(Cross-posted from TargetHIV)

BWF Sites Come Together to Celebrate the Resiliency of Black Women with HIV

To be resilient is to withstand and recover from difficult situations. For Black women with HIV, resilience is often expected but is rarely celebrated. In June 2022, staff from Grady Health System...

(Cross-posted from TargetHIV)

Each year, over 50,000 HIV care providers receive tailored HIV training from HRSA to better equip them to deliver HIV care to people with HIV with low incomes, according to a report from HRSA’s Ryan White HIV/AIDS Program (RWHAP). 

Trainings reached a mix of nurses, docto...

Click on each date/tab below to reveal the schedule of AETC Program sessions and poster presentations planned for the 2022 National Ryan White Conference on HIV Care & Treatment. The AETC National Coordinating Resource Center will also be exhibiting and promoting AETC Program training materials,...

Imagine: Ending HIV. It’s Possible. is the name of a new, national campaign that launched this summer to encourage and energize the HIV workforce to achieve the national goal of ending the HIV epidemic.

The U.S. Department of Health and Human Services introduced the Ending the HIV Epidemic in the U.S...

Pharmacists have been identified by the CDC as key professionals in achieving one of the CDC’s goals of Ending the HIV Epidemic in the U.S. by preventing HIV infection. Below are some of the most common questions received at the AETC National Clinician Consultation Center (NCCC) from pharmacists abo...

Imagine living in a state with the second highest rate of chlamydia and the third highest rate of congenital syphilis infections in the United States (U.S.) in 2018. Our first thought was how can this be, and our second thought was what can we do to overcome this? When we looked at the 2019 U.S. Cen...

The FDA recently approved the use of an extended-release injectable formulation of the integrase inhibitor cabotegravir (CAB) for preexposure prophylaxis (PrEP) for adults and adolescents at risk for HIV infection. After two initial intramuscular (IM) injections given 1 month apart, it is administer...

In December 2021, the U.S. Centers for Disease Control and Prevention issued thoroughly revised and updated PrEP guidelines. The guidelines include important new information on the use of oral PrEP (TDF/FTC and TAF/FTC) and recommendations on the use of injectable cabotegravir (CAB) as PrEP.

Key upda...

Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (GC) are the two most common bacterial sexually transmitted infections in the United States. The incidence of CT and GC have increased consistently since 2014, and current rates are at an all-time high. CT and GC infections are treatable with anti...

TANGO is a randomized open-label study in which subjects with virologic suppression on standard 3-drug TAF-based ART either switched to the 2-drug regimen of dolutegravir (DTG)/lamivudine (3TC) n = 369) or continued their baseline ART (n = 372). Previously published data showed no significant differ...

The FLAIR study evaluated the efficacy and safety of the long-acting injectable regimen of cabotegravir (CAB) + rilpivirine (RPV) in previously ART-naïve individuals who switched to CAB+RPV after viral suppression on a standard 3-drug oral regimen (dolutegravir [DTG]/ABC/3TC). At both 48 weeks (the...

Lenacapavir (LEN) is a novel investigational long-acting injectable ARV that is administered every 6 months by subcutaneous (SC) injection. It is an HIV-1 capsid inhibitor that acts at several points in the HIV life cycle. As a novel class, has full activity against viruses with resistance to the NR...